Background: Nabilone has been approved to treat chemotherapy-induced nausea and vomiting. Recent studies have explored cannabinoids in pain management.
Objectives: To review the evidence for the use of cannabinoids in general and nabilone in particular; i) in managing chemotherapy-induced nausea and vomiting; and ii) in treating pain.
Method: A systematic review of published English literature used the terms: cancer, cannabinoid, nabilone, nausea, pain, tetrahydrocannabinol and vomiting as search terms. Reviews, meta-analyses and treatment trials were reviewed.
Results/conclusions: Nabilone is superior to placebo, domperidone and prochlorperazine but not metoclopramide or chlorpromazine. Cannabinoids do not add to benefits of 5-HT(3) receptor antagonists. Side effects are greater for nabilone than for prochlorperazine, in most studies patients prefered nabilone over prochlorperazine. Nabilone is ineffective in acute pain but benefits in neuropathic pain and central hypersensitization. Recent guidelines place nabilone as a second to fourth line drug for neuropathic pain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543784.17.1.85 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extensive small cell lung cancer treated by integrated traditional Chinese and Western medicine: A case report.
Medicine (Baltimore)
January 2025
Department of Acupuncture and Moxibustion, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, P.R. China.
Rationale: Patients with extensive small cell lung cancer (SCLC) generally have a dismal survival rate and are conventionally treated with chemotherapy. This study aimed to explore an alternative treatment approach by combining traditional Chinese medicine (TCM) with radiotherapy and chemotherapy.
Patient Concerns: A 68-year-old male was diagnosed with extensive-stage SCLC.
Addition of an NK1 receptor antagonist to standard antiemetic prophylaxis in patients with B-cell lymphoma receiving EPOCH.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA.
Introduction: Data on the optimal management of patients with hematologic malignancies and chemotherapy-induced nausea and vomiting (CINV) are lacking, particularly for multiday chemotherapy regimens. We report our institutional experience in patients with B-cell lymphoma receiving multiday dose-adjusted R-EPOCH chemotherapy utilizing two CINV prophylaxis strategies.
Methods: We performed a retrospective, single-center, cohort study evaluating hospitalized patients with aggressive non-Hodgkin B-cell lymphoma receiving DA-R-EPOCH (April 2016 to October 2022).
[Integrative medicine : what's new in 2024].
Rev Med Suisse
January 2025
Centre de médecine intégrative et complémentaire, Service d'anesthésiologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
This article reports on new findings on integrative and complementary medicine published in 2024. The implementation of guidelines for the management of pain in cancer patients is discussed. Then, a literature review is presented, that aims to clarify the role of complementary approaches in the management of chemotherapy-induced nausea and vomiting and provides a concrete example of how recommendations are established.
View Article and Find Full Text PDFProspective clinical evidence from over 1,000 pan-cancer patients: a complement to fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting.
BMC Cancer
January 2025
The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Background: Chemotherapy-induced nausea and/or vomiting (CINV) is an intractable adverse effect of anticancer drugs. Although prophylactic use of fosaprepitant may be effective in reducing CINV, there is a lack of studies evaluating the application of fosaprepitant in real world.
Aims And Methods: This study prospectively observed the effectiveness and safety for the prophylaxis of CINV in a real-world clinical setting.
Effect of non-pharmacological interventions on chemotherapy induced delayed nausea and vomiting for tumors: A systematic review and Bayesian network meta-analysis.
Complement Ther Med
January 2025
School of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China. Electronic address:
Objective: To evaluate the efficacy of non-pharmacological interventions in improving chemotherapy induced delayed nausea and vomiting symptoms using a network meta-analysis.
Methods: Four Chinese databases (CNKI, Wanfang Data Knowledge Service Platform, VIP, Sinomed) and five English databases (PubMed, Cochrane Library, Embase, Web of Science, CINAHL) were searched from the establishment of the database to April 2024. A Bayesian network meta-analysis was performed on the response rate to the improvement of chemotherapy induced delayed nausea and vomiting, as well as improvement in KPS score, under different non-pharmacological interventions by using R 4.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!